201 related articles for article (PubMed ID: 38062391)
1. Incorporating mutational heterogeneity to identify genes that are enriched for synonymous mutations in cancer.
Rao Y; Ahmed N; Pritchard J; O'Brien EP
BMC Bioinformatics; 2023 Dec; 24(1):462. PubMed ID: 38062391
[TBL] [Abstract][Full Text] [Related]
2. A pan-cancer analysis of synonymous mutations.
Sharma Y; Miladi M; Dukare S; Boulay K; Caudron-Herger M; Groß M; Backofen R; Diederichs S
Nat Commun; 2019 Jun; 10(1):2569. PubMed ID: 31189880
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different functional prediction scores using a gene-based permutation model for identifying cancer driver genes.
Nono AD; Chen K; Liu X
BMC Med Genomics; 2019 Jan; 12(Suppl 1):22. PubMed ID: 30704472
[TBL] [Abstract][Full Text] [Related]
4. Candidate Cancer Driver Mutations in Distal Regulatory Elements and Long-Range Chromatin Interaction Networks.
Zhu H; Uusküla-Reimand L; Isaev K; Wadi L; Alizada A; Shuai S; Huang V; Aduluso-Nwaobasi D; Paczkowska M; Abd-Rabbo D; Ocsenas O; Liang M; Thompson JD; Li Y; Ruan L; Krassowski M; Dzneladze I; Simpson JT; Lupien M; Stein LD; Boutros PC; Wilson MD; Reimand J
Mol Cell; 2020 Mar; 77(6):1307-1321.e10. PubMed ID: 31954095
[TBL] [Abstract][Full Text] [Related]
5. An analysis of mutational signatures of synonymous mutations across 15 cancer types.
Bin Y; Wang X; Zhao L; Wen P; Xia J
BMC Med Genet; 2019 Dec; 20(Suppl 2):190. PubMed ID: 31815613
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and architecture of posttranscriptionally impaired synonymous mutations in 8,320 genomes across 22 cancer types.
Teng H; Wei W; Li Q; Xue M; Shi X; Li X; Mao F; Sun Z
Nucleic Acids Res; 2020 Feb; 48(3):1192-1205. PubMed ID: 31950163
[TBL] [Abstract][Full Text] [Related]
7. Identification of coding and non-coding mutational hotspots in cancer genomes.
Piraino SW; Furney SJ
BMC Genomics; 2017 Jan; 18(1):17. PubMed ID: 28056774
[TBL] [Abstract][Full Text] [Related]
8. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma.
Gartner JJ; Parker SC; Prickett TD; Dutton-Regester K; Stitzel ML; Lin JC; Davis S; Simhadri VL; Jha S; Katagiri N; Gotea V; Teer JK; Wei X; Morken MA; Bhanot UK; ; Chen G; Elnitski LL; Davies MA; Gershenwald JE; Carter H; Karchin R; Robinson W; Robinson S; Rosenberg SA; Collins FS; Parmigiani G; Komar AA; Kimchi-Sarfaty C; Hayward NK; Margulies EH; Samuels Y
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13481-6. PubMed ID: 23901115
[TBL] [Abstract][Full Text] [Related]
9. Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Lawrence MS; Stojanov P; Polak P; Kryukov GV; Cibulskis K; Sivachenko A; Carter SL; Stewart C; Mermel CH; Roberts SA; Kiezun A; Hammerman PS; McKenna A; Drier Y; Zou L; Ramos AH; Pugh TJ; Stransky N; Helman E; Kim J; Sougnez C; Ambrogio L; Nickerson E; Shefler E; Cortés ML; Auclair D; Saksena G; Voet D; Noble M; DiCara D; Lin P; Lichtenstein L; Heiman DI; Fennell T; Imielinski M; Hernandez B; Hodis E; Baca S; Dulak AM; Lohr J; Landau DA; Wu CJ; Melendez-Zajgla J; Hidalgo-Miranda A; Koren A; McCarroll SA; Mora J; Crompton B; Onofrio R; Parkin M; Winckler W; Ardlie K; Gabriel SB; Roberts CWM; Biegel JA; Stegmaier K; Bass AJ; Garraway LA; Meyerson M; Golub TR; Gordenin DA; Sunyaev S; Lander ES; Getz G
Nature; 2013 Jul; 499(7457):214-218. PubMed ID: 23770567
[TBL] [Abstract][Full Text] [Related]
10. Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations.
Poulos RC; Wong YT; Ryan R; Pang H; Wong JWH
PLoS Genet; 2018 Nov; 14(11):e1007779. PubMed ID: 30412573
[TBL] [Abstract][Full Text] [Related]
11. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
McGranahan N; Favero F; de Bruin EC; Birkbak NJ; Szallasi Z; Swanton C
Sci Transl Med; 2015 Apr; 7(283):283ra54. PubMed ID: 25877892
[TBL] [Abstract][Full Text] [Related]
12. Synonymous mutations that regulate translation speed might play a non-negligible role in liver cancer development.
Li Q; Li J; Yu CP; Chang S; Xie LL; Wang S
BMC Cancer; 2021 Apr; 21(1):388. PubMed ID: 33836673
[TBL] [Abstract][Full Text] [Related]
13. Combined burden and functional impact tests for cancer driver discovery using DriverPower.
Shuai S; ; Gallinger S; Stein LD;
Nat Commun; 2020 Feb; 11(1):734. PubMed ID: 32024818
[TBL] [Abstract][Full Text] [Related]
14. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations.
Diederichs S; Bartsch L; Berkmann JC; Fröse K; Heitmann J; Hoppe C; Iggena D; Jazmati D; Karschnia P; Linsenmeier M; Maulhardt T; Möhrmann L; Morstein J; Paffenholz SV; Röpenack P; Rückert T; Sandig L; Schell M; Steinmann A; Voss G; Wasmuth J; Weinberger ME; Wullenkord R
EMBO Mol Med; 2016 May; 8(5):442-57. PubMed ID: 26992833
[TBL] [Abstract][Full Text] [Related]
15. Passenger Mutations in More Than 2,500 Cancer Genomes: Overall Molecular Functional Impact and Consequences.
Kumar S; Warrell J; Li S; McGillivray PD; Meyerson W; Salichos L; Harmanci A; Martinez-Fundichely A; Chan CWY; Nielsen MM; Lochovsky L; Zhang Y; Li X; Lou S; Pedersen JS; Herrmann C; Getz G; Khurana E; Gerstein MB
Cell; 2020 Mar; 180(5):915-927.e16. PubMed ID: 32084333
[TBL] [Abstract][Full Text] [Related]
16. Pathway and network analysis of more than 2500 whole cancer genomes.
Reyna MA; Haan D; Paczkowska M; Verbeke LPC; Vazquez M; Kahraman A; Pulido-Tamayo S; Barenboim J; Wadi L; Dhingra P; Shrestha R; Getz G; Lawrence MS; Pedersen JS; Rubin MA; Wheeler DA; Brunak S; Izarzugaza JMG; Khurana E; Marchal K; von Mering C; Sahinalp SC; Valencia A; ; Reimand J; Stuart JM; Raphael BJ;
Nat Commun; 2020 Feb; 11(1):729. PubMed ID: 32024854
[TBL] [Abstract][Full Text] [Related]
17. Depletion of somatic mutations in splicing-associated sequences in cancer genomes.
Hurst LD; Batada NN
Genome Biol; 2017 Nov; 18(1):213. PubMed ID: 29115978
[TBL] [Abstract][Full Text] [Related]
18. Nonsynonymous, synonymous and nonsense mutations in human cancer-related genes undergo stronger purifying selections than expectation.
Chu D; Wei L
BMC Cancer; 2019 Apr; 19(1):359. PubMed ID: 30991970
[TBL] [Abstract][Full Text] [Related]
19. Non-coding cancer driver candidates identified with a sample- and position-specific model of the somatic mutation rate.
Juul M; Bertl J; Guo Q; Nielsen MM; Świtnicki M; Hornshøj H; Madsen T; Hobolth A; Pedersen JS
Elife; 2017 Mar; 6():. PubMed ID: 28362259
[TBL] [Abstract][Full Text] [Related]
20. Mutational landscape of RNA-binding proteins in human cancers.
Neelamraju Y; Gonzalez-Perez A; Bhat-Nakshatri P; Nakshatri H; Janga SC
RNA Biol; 2018 Jan; 15(1):115-129. PubMed ID: 29023197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
